The stock has a 36-month beta value of 0.78. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for KURA is 65.25M, and at present, short sellers hold a 13.62% of that float. On December 26, 2024, the average trading volume of KURA was 1.52M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KURA) stock’s latest price update
Kura Oncology Inc (NASDAQ: KURA)’s stock price has plunge by -0.89relation to previous closing price of 8.94. Nevertheless, the company has seen a -8.52% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-18 that Kura Oncology, Inc.’s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura’s lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.
KURA’s Market Performance
Kura Oncology Inc (KURA) has experienced a -8.52% fall in stock performance for the past week, with a -17.50% drop in the past month, and a -54.47% drop in the past quarter. The volatility ratio for the week is 4.59%, and the volatility levels for the past 30 days are at 4.88% for KURA. The simple moving average for the past 20 days is -12.56% for KURA’s stock, with a -52.86% simple moving average for the past 200 days.
Analysts’ Opinion of KURA
Many brokerage firms have already submitted their reports for KURA stocks, with UBS repeating the rating for KURA by listing it as a “Buy.” The predicted price for KURA in the upcoming period, according to UBS is $27 based on the research report published on October 24, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see KURA reach a price target of $19, previously predicting the price at $26. The rating they have provided for KURA stocks is “Hold” according to the report published on October 14th, 2024.
Mizuho gave a rating of “Buy” to KURA, setting the target price at $26 in the report published on December 22nd of the previous year.
KURA Trading at -36.98% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.34% of loss for the given period.
Volatility was left at 4.88%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares sank -19.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.94% lower at present.
During the last 5 trading sessions, KURA fell by -9.03%, which changed the moving average for the period of 200-days by -61.17% in comparison to the 20-day moving average, which settled at $10.13. In addition, Kura Oncology Inc saw -38.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from FORD KATHLEEN, who sale 526 shares at the price of $16.03 back on Nov 18 ’24. After this action, FORD KATHLEEN now owns 23,184 shares of Kura Oncology Inc, valued at $8,434 using the latest closing price.
FORD KATHLEEN, the Officer of Kura Oncology Inc, proposed sale 526 shares at $15.99 during a trade that took place back on Nov 18 ’24, which means that FORD KATHLEEN is holding shares at $8,410 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -171.26 for the present operating margin
- 0.49 for the gross margin
The net margin for Kura Oncology Inc stands at -155.55. The total capital return value is set at -0.5. Equity return is now at value -46.28, with -41.48 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.85. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -135.09.
Currently, EBITDA for the company is -164.96 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 516.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.47.
Conclusion
To sum up, Kura Oncology Inc (KURA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
